SIC
DNLI icon

SJS Investment Consulting’s Denali Therapeutics DNLI Stock Holding History

SJS Investment Consulting’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.61K Buy
218
+202
+1,263% +$4.15K ﹤0.01% 1339
2026
Q1 		$308 Buy
16
+12
+300% +$239 ﹤0.01% 1888
2025
Q4 		$67 Hold
4
– – ﹤0.01% 1993
2025
Q3 		$59 Hold
4
– – ﹤0.01% 1598
2025
Q2 		$56 Buy
4
+1
+33% +$14 ﹤0.01% 1508
2025
Q1 		$41 Buy
+3
New +$57 ﹤0.01% 1572

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SJS Investment Consulting's DNLI Position: Q2 2026 in Review

SJS Investment Consulting increased its Denali Therapeutics (DNLI) stake by 1,263% in Q2 2026, buying an estimated $4.15K and bringing the position to 218 shares worth $5.61K. The position accounts for ﹤0.01% of the portfolio, ranked #1339.

SJS Investment Consulting first reported a position in DNLI in Q1 2025 and has held it in 6 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • SJS Investment Consulting held 218 shares of Denali Therapeutics worth $5.61K as of Q2 2026.
  • SJS Investment Consulting bought 202 Denali Therapeutics shares in Q2 2026, an estimated $4.15K.
  • Denali Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1339 holding.
  • SJS Investment Consulting first reported a position in Denali Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.